Home | Screening data | Screen comparisons | Search for compounds | Structure search

Compound InformationSONAR Target prediction
Name:

HYDROCORTISONE

Unique Identifier:SPE00300024
MolClass: Checkout models in ver1.5 and ver1.0
Molecular Formula:
Molecular Weight:332.222 g/mol
X log p:-0.726  (online calculus)
Lipinksi Failures0
TPSA34.14
Hydrogen Bond Donor Count:0
Hydrogen Bond Acceptors Count:5
Rotatable Bond Count:2
Canonical Smiles:CC12CCC(=O)C=C1CCC1C3CCC(O)(C(=O)CO)C3(C)CC(O)C12
Class:sterol
Source:adrenal glands
Therapeutics:glucocorticoid, antiinflammatory
Generic_name:Hydrocortisone
Chemical_iupac_name:11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahyd
ro-1H-cyclopenta[a]phenanthren-3-one
Drug_type:Approved Drug
Pharmgkb_id:PA449905
Kegg_compound_id:C00735
Drugbank_id:APRD01019
Melting_point:220 oC
H2o_solubility:320 mg/L
Logp:1.692
Cas_registry_number:50-23-7
Mass_spectrum:http://webbook.nist.gov/cgi/cbook.cgi?Spec=C50237&Index=0&Type=Mass&Large=on
Drug_category:Anti-Inflammatory Agents; ATC:A01AC03; ATC:A07EA02; ATC:C05AA01; ATC:D07AA02;
ATC:D07AB02; ATC:D07AB11; ATC:D07AC16; ATC:D07XA01; ATC:H02AB09; ATC:S01BA02;
ATC:S01CB03; ATC:S02BA01
Indication:For the relief of the inflammatory and pruritic manifestations of
corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal)
disorders (adrenal insufficiency, Addisons disease). It is also used to treat many
immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe
asthma, ulcerative colitis, and Crohn-s disease.
Pharmacology:Hydrocortisone is the most important human glucocorticoid. It is essential for life
and regulates or supports a variety of important cardiovascular, metabolic,
immunologic and homeostatic functions. Topical hydrocortisone is used for its
anti-inflammatory or immunosuppressive properties to treat inflammation due to
corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid
hormones characterised by an ability to bind with the cortisol receptor and trigger
a variety of important cardiovascular, metabolic, immunologic and homeostatic
effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids
by having different receptors, target cells, and effects. Technically, the term
corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often
used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated
immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3,
IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2.
Reduced cytokine production limits T cell proliferation. Glucocorticoids also
suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2
receptors. This diminishes both B cell clonal expansion and antibody synthesis. The
diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.
Mechanism_of_action:Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the
receptor the newly formed receptor-ligand complex translocates itself into the cell
nucleus, where it binds to many glucocorticoid response elements (GRE) in the
promoter region of the target genes. The DNA bound receptor then interacts with
basic transcription factors, causing the increase in expression of specific target
genes. The anti-inflammatory actions of corticosteroids are thought to involve
lipocortins, phospholipase A2 inhibitory proteins which, through inhibition
arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes.
Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then
binds to cell membranes preventing the phospholipase A2 from coming into contact
with its substrate arachidonic acid. This leads to diminished eicosanoid production.
The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed,
potentiating the effect. In another words, the two main products in inflammation
Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids.
Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space,
where it binds to the leukocyte membrane receptors and inhibits various inflammatory
events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst
and the release of various inflammatory mediators (lysosomal enzymes, cytokines,
tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and
mastocytes. Additionally the immune system is suppressed by corticosteroids due to a
decrease in the function of the lymphatic system, a reduction in immunoglobulin and
complement concentrations, the precipitation of lymphocytopenia, and interference
with antigen-antibody binding.
Organisms_affected:Humans and other mammals

Found: 205 nonactive as graph: single | with analogs [1] << Back 161 162 163 164 165 166 167 168 169 170  Next >> [205]
Species: 4932
Condition: NAT1
Replicates: 2
Raw OD Value: r im 0.7208±0.000353553
Normalized OD Score: sc h 1.0074±0.00341861
Z-Score: 0.4455±0.190308
p-Value: 0.65889
Z-Factor: -12.5056
Fitness Defect: 0.4172
Bioactivity Statement: Nonactive
Experimental Conditions
Library:SPECMTS3
Plate Number and Position:7|F9
Drug Concentration:50.00 nM
OD Absorbance:600 nm
Robot Temperature:26.30 Celcius
Date:2008-06-26 YYYY-MM-DD
Plate CH Control (+):0.040675±0.00048
Plate DMSO Control (-):0.690925±0.02257
Plate Z-Factor:0.8913
png
ps
pdf

DBLink | Rows returned: 45<< Back 1 2 3 4 5 6 7 8 Next >> 
7059529 (8S,9R,10R,11R,13R,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16
-decahydro-1H-cyclopenta[a]phenanthren-3-one
7059530 (8R,9R,10S,11R,13R,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16
-decahydro-1H-cyclopenta[a]phenanthren-3-one
7059531 (8R,9R,10R,11R,13R,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16
-decahydro-1H-cyclopenta[a]phenanthren-3-one
7061014 (8S,9S,10R,11R,13S,14R,16R,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-2,6,7,8,9,11,12,
14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
7061015 (8S,9S,10R,11R,13S,14S,16R,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-2,6,7,8,9,11,12,
14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
7061016 (8S,9R,10R,11R,13S,14R,16R,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-2,6,7,8,9,11,12,
14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one

internal high similarity DBLink | Rows returned: 5
LOPAC 01179 0.9038
NRB 03831 0.9231
SPE01500380 0.9231
LOPAC 00759 0.9615
LOPAC 00948 1.0000

active | Cluster 10196 | Additional Members: 12 | Rows returned: 0

Service provided by the Mike Tyers Laboratory